Augustin L.
- Country
- France
- Department
- Rheumatology
Research Overview
- Efficacy and Safety of Topical Clobetasol Propionate versus Placebo in Adult Patients with Inflammatory Hand Osteoarthritis: A Randomized Controlled Trial
- Randomized Controlled Trial Comparing Methotrexate or Leflunomide with Targeted Therapy Versus Triple Therapy in Rheumatoid Arthritis Patients Unresponsive to Methotrexate or Leflunomide
- Randomized, Double-Blind, Multicenter Trial of Tocilizumab Versus Placebo in Refractory Chronic Inflammatory Chondrocalcinosis
Data & Insights
Has run more than one trial at 12 of 44 partner sites.
Specializations
Rheumatology Focus
The investigator specializes in treating rheumatoid arthritis, with particular emphasis on advanced therapeutic approaches for patients who show insufficient response to conventional treatments.
- Autoimmune Disease Management
- Treatment-Resistant RA
- Combination Therapy Approaches
Primary interest lies in comparing the effectiveness of various therapeutic combinations for managing rheumatoid arthritis symptoms and disease progression.
Therapeutic Innovation
Focuses on evaluating the comparative efficacy of targeted therapies against traditional combination treatments in rheumatology care.
- Advanced Treatment Protocols
- Therapeutic Strategy Optimization
- Treatment Response Assessment
Investigates innovative therapeutic approaches for patients who require alternative treatment strategies.
Treatment Optimization
Specializes in developing improved treatment protocols for patients with inadequate response to conventional therapies.
- Treatment Effectiveness Analysis
- Disease Management Strategies
- Patient Response Evaluation
Works to identify optimal therapeutic combinations for enhanced patient outcomes in rheumatoid arthritis treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.